C.N.Sternberg
F.Saad
J.N.Graff
A.Peer
U.N.Vaishampayan
E.Leung
E.Rosenbaum
H.Gurney
R.J.Epstein
I.D.Davis
L.Trandafir
V.J.Wagner
M.Hussain
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY.
Montreal Cancer Institute, Montreal University Hospital Center (CHUM), Montreal, QC, Canada
Knight Cancer Institute, Oregon Health and Science University and VA Portland Health Care System, Portland, USA
Department of Oncology, Rambam Medical Center, Haifa, Israel
Department of Oncology, Wayne State University and Karmanos Cancer Institute, Detroit, MI
Division of Nuclear Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada
Institute of Oncology, Rabin Medical Center-Davidoff Cancer Center, Petah Tikva, Israel
Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, Australia
Department of Medical Oncology, The Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney, Australia
Department of Paediatrics, Monash University, Melbourne, Australia
Austin Health, Melbourne, Australia
Clinical Statistics Oncology, Bayer HealthCare Pharmaceutical Inc, Whippany, USA
Global Clinical Development, Bayer Consumer Care AG, Basel, Switzerland
Division of Hematology/Oncology, Robert H. Lurie Cancer Center Northwestern University Feinberg School of Medicine, Chicago, IL
United States
Canada
Israel
Australia
Switzerland
N/A
Urology
Oncology (ONC)
Metastatic castration-resistant prostate cancer
N/A
Radium-223 Dichloride
N/A
Randomized
II
NCT02023697
N/A
N/A